Among the ranks of large pharmaceutical companies this year, there was a clear standout: Bristol-Myers Squibb. Pfizer, Abbott Laboratories, and Eli Lilly all managed to notch share price increases of greater than 15%. So did Amgen, which continued to define the border between the biotechnology companies and big pharma, which it looks a bit more like every single year.
